BIOAXONE BIOSCIENCES, INC.
Biotech · Private
Small molecule inhibitor (BA) targeting ROCK protein kinase for spinal cord injury recovery
bioaxonebio.com →- Grants
- $8.6M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 26
- 13 granted · 13 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Combination of BA-210 and digestion of the glial scar in chronic spinal cord injury | $319,201 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of BA-1049 for treatment of cerebral cavernous malformation | $280,625 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of BA for treatment of cerebral cavernous malformation | $3,007,087 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of BA-1049 for treatment of cerebral cavernous malformation | $1,430,655 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of BA-1049 for treatment of cerebral cavernous malformation | $1,576,432 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of self-delivering RNAi targeted to PTEN for treatment of spinal cord injury | $735,822 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of self-delivering RNAi targeted to PTEN for treatment of spinal cord injury | $1,059,073 | |
| Federal grant | Department of Health and Human Services · Phase I · An oral ROCK2-selective inhibitor for treatment of chronic spinal cord injury | $224,454 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2058 | SAB CAPRA, LLC | — | — |
| 2059 | Angitia Biopharmaceuticals | — | — |
| 2060 | RADTRAN LLC | — | — |
| 2061 | BIOAXONE BIOSCIENCES, INC. | — | — |
| 2062 | Synthetic Biodesign, LLC | — | — |
| 2063 | Silverpeutics Inc. | — | $12M |
| 2064 | General Probiotics Inc | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Treatment Of Cerebral Cavernous Malformations And Cerebral Aneurysms With Rho Kinase Inhibitorsgranted
- Rho Kinase Inhibitor BA-1049 (r) And Active Metabolites Thereofgranted
- Rho Kinase Inhibitor BA-1049 (r) And Active Metabolites Thereofgranted
- Treatment Of Cerebral Cavernous Malformations And Cerebral Aneurysms With Rho Kinase Inhibitorsgranted
- C3 Fusion Protein And Methods Of Making And Using Thereofapplication
- C3 Fusion Protein And Methods Of Making And Using Thereofgranted
- TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICSapplication
- Rho Kinase Inhibitor BA-1049 (r) And Active Metabolites Thereofgranted
- TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICSgranted
- Treatment Of Cerebral Cavernous Malformations And Cerebral Aneurysms With Rho Kinase Inhibitorsgranted
- Kinase Inhibitors For Treatment Of Diseasegranted
- Rho Kinase Inhibitor BA-1049 (r) And Active Metabolites Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.